Yahoo
NasdaqCM - Delayed Quote USD

enGene Therapeutics Inc. (ENGNW)

0.1813 0.0000 (0.00%)
At close: October 28 at 1:18:24 PM EDT
Chart Range Bar
Loading chart for ENGNW
  • Previous Close 0.1813
  • Open 2.1000
  • Bid --
  • Ask --
  • Day's Range 0.1813 - 0.1831
  • 52 Week Range 0.1813 - 0.1831
  • Volume 0
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) -0.24
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

www.engene.com

81

Full Time Employees

--

Fiscal Year Ends

--

Sector

--

Industry

Recent News

View More

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -32.5M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-30M
-20M
-10M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.00%

  • Return on Equity (ttm)

    -60.50%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -130.36M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    266.32M

  • Total Debt/Equity (mrq)

    14.45%

  • Levered Free Cash Flow (ttm)

    -60.85M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: